3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
46
NET
41
CNS
14
Gastrointestinal
8
Thoracic
2
Dermatologic
2
Sarcoma
1
Other neoplasm
1
Head & Neck
1
Genitourinary
1
Breast
1
Conditions
Sarcoma, Synovial
1
Recurrence
1
Pheochromocytoma
1
Paraganglioma
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Meningioma
1
Medulloblastoma
1
Glioma
1
Glioblastoma
1
Esthesioneuroblastoma, Olfactory
1
Ependymoma
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
Radiotherapy
216
Cyclophosphamide
211
Doxorubicin
207
Temozolomide
181
Ifosfamide
121
Filgrastim
111
Etoposide
101
Imatinib Mesylate
99
Vincristine
92
Gemcitabine
89
Bevacizumab
83
Magnetic Resonance Spectroscopy
79
Irinotecan
79
pembrolizumab
75
Radiation
67
Carboplatin
65
pazopanib
60
Methotrexate
60
Nivolumab
58
Cisplatin
58
fludarabine phosphate
56
Peripheral Blood Stem Cell Transplantation
56
Specimen Handling
53
Docetaxel
50
Busulfan
48
Trabectedin
47
Biopsy
47
Melphalan
46
Surgical Procedures, Operative
45
Paclitaxel
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
lutetium Lu 177 dotatate
×
Sarcoma
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled